Back to top

Image: Bigstock


Read MoreHide Full Article

Biogen’s fourth quarter results were mixed with earnings coming in way above expectations and revenues missing slightly. The company provided a strong outlook for 2015. Tecfidera should continue to perform well in the U.S. and EU and is expected to be the largest contributor to top-line growth in 2015. Biogen, which launched several new products in the last few months, remains poised for strong growth. The company also has several pipeline events lined up for 2015. However, the label update of Tecfidera in the U.S. for the PML case as well as the launch of Plegridy, which has been capturing some interferon switches that could have otherwise gone to Tecfidera, could moderate Tecfidera’s growth rate.

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Biogen Inc. (BIIB) - free report >>

Published in